X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.biospace.com/article/releases/redhill-biopharma-announces-36-million-strategic-investment-by-cosmo-pharmaceuticals-and-u-s-rights-to-approved-travelers-diarrhea-drug-aemcolo/?s=95
https://blogs.sciencemag.org/pipeline/archives/2019/02/04/2018-drug-approvals-a-closer-look?r3f_986=https://www.google.com/
https://www.fiercepharma.com/marketing/cosmo-to-give-bausch-health-sales-a-run-latest-fda-nod-for-xifaxan-rival
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626121.htm?utm_campaign=FDA%20approves%20new%20treatment%20of%20travelers%E2%80%99%20diarrhea%20caused%20by%20noninvasive%20strains%20of%20Escherichia%20coli&utm_medium=email&utm_source=Eloqua
https://www.prnewswire.com/news-releases/fda-accepts-new-drug-application-for-aemcolo-rifamycin-sv-mmx-and-sets-pdufa-date-for-november-16-2018-300651877.html
https://seekingalpha.com/article/4158489-valeant-rifamycin-threat-devastating
https://www.fiercepharma.com/marketing/valeant-partner-cosmo-turns-wannabe-ibs-d-rival-and-it-could-do-some-sales-damage-analyst
http://portal.anvisa.gov.br/wps/content/anvisa+portal/anvisa/sala+de+imprensa/menu+-+noticias+anos/2015/anvisa+suspende+dois+medicamentos+da+ems
Market Place
Share 
